I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Leppa, S.
150
results:
Search for persons
X
Format
Online (150)
Mediatypes
Articles (Online) (58)
OpenAccess-fulltext (92)
Languages
english (140)
finnish (1)
Sorted by: Relevance
Sorted by: Year
?
1
Final safety and efficacy results of copanlisib monotherapy..:
Dreyling, M.
;
Santoro, A.
;
Mollica, L.
...
Hematological Oncology. 41 (2023) S2 - p. 560-562 , 2023
Link:
https://doi.org/10.1002/..
?
2
Enhanced ctDNA Profiling Reveals Molecular Determinants of ..:
Meriranta, L.
;
Kolstad, A.
;
Hutchings, M.
...
Hematological Oncology. 41 (2023) S2 - p. 477-478 , 2023
Link:
https://doi.org/10.1002/..
?
3
LONG‐TERM FOLLOW‐UP AND GENE EXPRESSION PROFILES ASSOCIATED..:
Relander, T.
;
Leivonen, S.
;
Larsen, T. S.
...
Hematological Oncology. 41 (2023) S2 - p. 309-310 , 2023
Link:
https://doi.org/10.1002/..
?
4
BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH‐RISK LARGE B‐CE..:
Leppa, S.
;
Meriranta, L.
;
Arffman, M.
...
Hematological Oncology. 41 (2023) S2 - p. 51-52 , 2023
Link:
https://doi.org/10.1002/..
?
5
TOBACCO SMOKING IMPAIRS SURVIVAL IN LYMPHOMA PATIENTS IN TW..:
Reunamo, T.
;
Mikkola, T.
;
Laitinen, T.
...
Hematological Oncology. 41 (2023) S2 - p. 612-613 , 2023
Link:
https://doi.org/10.1002/..
?
6
GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY..:
Dickinson, M.
;
Carlo‐Stella, C.
;
Morschhauser, F.
...
Hematological Oncology. 41 (2023) S2 - p. 144-146 , 2023
Link:
https://doi.org/10.1002/..
?
7
EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DUR..:
Belada, D.
;
Falchi, L.
;
Leppä, S.
...
Hematological Oncology. 41 (2023) S2 - p. 125-127 , 2023
Link:
https://doi.org/10.1002/..
?
8
P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIM..:
Belada, D.
;
Leppä, S.
;
Wahlin, B. E.
...
HemaSphere. 6 (2022) - p. 1025-1026 , 2022
Link:
https://doi.org/10.1097/..
?
9
HIGH RISK AGGRESSIVE B‐CELL LYMPHOMA ON THE LIQUID BIOPSY:
Meriranta, L
;
Alkodsi, A
;
Pasanen, A
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
10
CHARACTERIZATION OF CANCER ASSOCIATED FIBROBLASTS IN CLASSI..:
Karihtala, K.
;
Leivonen, S.‐K.
;
Karjalainen‐Lindsberg, M.‐L.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
11
BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH RISK DIFFUSE LA..:
Leppä, S
;
Jørgensen, J
;
Karjalainen‐Lindsberg, M‐L
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
12
FINAL ANALYSIS OF A NORDIC LYMPHOMA GROUP PHASE IB/IIA TRIA..:
d'Amore, F
;
Leppä, S
;
Relander, T
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
13
Intravenous but not intrathecal central nervous system–dire..:
Mannisto, S.
;
Vähämurto, P.
;
Pollari, M.
...
European Journal of Cancer. 115 (2019) - p. 27-36 , 2019
Link:
https://doi.org/10.1016/..
?
14
PROGNOSTIC VALUE OF BASELINE FDG PET PARAMETERS IN HIGH RIS..:
Fiskvik, I.
;
Stokke, C.
;
Mikalsen, L.G.
...
Hematological Oncology. 37 (2019) S2 - p. 411-411 , 2019
Link:
https://doi.org/10.1002/..
?
15
EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY IND..:
Dreyling, M.
;
Santoro, A.
;
Leppä, S.
...
Hematological Oncology. 37 (2019) S2 - p. 387-389 , 2019
Link:
https://doi.org/10.1002/..
1-15